Questions on MannKind’s inhaled insulin PhIII data cloud Afrezza’s future

John Carroll

Early yesterday MannKind's Phase III for Afrezza looked like a big hit with investors. But after a second look at the trial results, analysts' enthusiasm–and MannKind's share price–waned.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS